개요
만성 염증 치료제의 시장 동향은 기술 발전의 증가로 인해 제품 출시가 증가하고 있음을 보여줍니다. 몇 개월에서 몇 년 동안 지속되는 염증을 만성 염증 치료로 알려져 있습니다. 만성 염증 치료의 강도와 효과의 주요 결정 요인은 외상의 원인과 손상을 복구하고 복원하는 신체의 능력입니다.
또한, 검사 및 약물의 가용성 증가와 시장에서 비특이적 증식성 만성 염증 치료제의 수가 증가함에 따라 만성 염증 치료를 위한 제품 채택이 증가하고 있으며, 연구 개발이 증가함에 따라 만성 염증 치료제의 시장 규모가 확대되고 있습니다.
이 분야의 발전으로 인해 북미 지역에서 제품에 대한 수요가 증가하고 있으며, Pfizer Inc, NodThera, Abcentra, Halia Therapeutics, Inc.
다이나믹스
주요 기업의 발전과 임상시험의 증가는 만성 염증 치료 시장의 성장을 견인할 것입니다.
만성 염증성 질환은 지난 수십 년 동안 특히 서유럽 선진국에서 발생률과 유병률이 증가하고 있습니다. 염증과 통증을 줄이기 위해 여러 비스테로이드성 항염증제(NSAID)가 사용되고 있지만, 부작용이 없거나 미미한 식물성 천연 약품과는 달리 이러한 항염증제는 다양한 심각한 부작용을 가지고 있습니다.
나노입자는 높은 약물 충전 능력과 특정 세포 및 조직에 대한 높은 표적 선택성으로 인해 치료제로서의 생체 이용률을 높이고 약동학 및 약력학(PKPD)을 개선할 수 있는 새로운 유형의 약물전달 시스템입니다. 이러한 장점으로 인해 예측 기간 동안 시장은 주도적인 위치를 차지할 것으로 예상됩니다.
연구개발 및 신제품 출시 증가로 시장 성장 기회 창출
수년간의 연구 결과, 현재 많은 대형 제조업체들이 새로운 제품을 개발하여 치료 목적으로 출시하고 있으며, 이는 만성 염증 치료 시장의 확대를 촉진하고 있습니다. 일부 치료제는 만성 염증 관리 약물로 규제 당국의 승인을 받았습니다.
예를 들어, 2021년 2월 12일 미국 식품의약국(FDA)은 말초 신경을 침범하는 만성 염증성 탈수초성 다발성 신경병증(CIDP)으로 알려진 희귀 신경질환 성인 환자를 치료하기 위해 PANZYGA-ifas 10% 액상형 생물학적 제제 추가 승인 신청서를 승인했습니다. 환자의 임상적 요구에 부응하기 위해 판지가는 FDA가 CIDP에 대한 두 가지 유지 용량을 승인한 유일한 정맥주사용 면역글로불린 제제(IVIg)입니다.
만성염증치료제의 부작용으로 시장 성장 저해
만성 염증 치료제는 몇 가지 부작용이 있어 시장 성장을 저해할 수 있습니다. 가장 흔한 소화기 부작용은 복통, 메스꺼움, 설사이며, 환자의 20-30%가 경험하고 자연적으로 치유되는 경우가 많습니다. 젖산증은 더 심각한 부작용으로 매년 10만 명당 1.5명에 불과합니다.
메트포르민은 일반적으로 안전하다고 여겨지지만, 젖산증이라는 심각한 부작용이 있습니다. 이 질환은 혈액에 근육과 적혈구가 생성하는 화학제품인 젖산이 과도하게 함유되어 있을 때 발생합니다. 일반적으로 젖산 수치는 낮습니다.
목차
제1장 조사 방법과 조사 범위
제2장 정의와 개요
제3장 주요 요약
제4장 시장 역학
- 영향요인
- 성장 촉진요인
- 주요 기업에 의한 진보와 임상시험 증가
- 만성 염증성 질환 증가
- 성장 억제요인
- 기회
- 영향 분석
제5장 산업 분석
- Porter's Five Forces 분석
- 공급망 분석
- 가격 분석
- 규제 분석
- 파이프라인 분석
- 특허 분석
- SWOT 분석
제6장 COVID-19 분석
제7장 종류별
제8장 약제별
- 메트포르민
- 비스테로이드성 항염증제(NSAID)
- 스타틴
- 코르티코스테로이드
- 허브 보충제
제9장 만성 염증성 질환 종류별
- 당뇨병
- 심혈관질환
- 관절염 및 관절 질환
- 만성폐쇄성폐질환(COPD)
- 알레르기
- 기타
제10장 유통 채널별
제11장 지역별
- 북미
- 유럽
- 남미
- 아시아태평양
- 중동 및 아프리카
제12장 경쟁 상황
- 경쟁 시나리오
- 시장 상황/점유율 분석
- M&A 분석
제13장 기업 개요
- Pfizer Inc.
- 기업 개요
- 제품 포트폴리오와 설명
- 재무 개요
- 주요 동향
- NodThera
- Abcentra
- Evommune, Inc.
- Sterna biologicals
- Halia Therapeutics, Inc.
- Amgen Inc.
- AstraZeneca
- Takeda Pharmaceutical Company Limited
- Annexon, Inc.
제14장 부록
ksm
Overview
The chronic inflammation treatment market trends show rising product launches owing to the rising technological advancements. Inflammation that lasts for a few months to years is known as chronic inflammation treatment. The cause of the trauma and the ability of the body to repair and undo the harm are the main determinants of the intensity and effects of chronic inflammation treatment.
Furthermore, rising adoption of products for chronic inflammation treatment due to the rising availability of tests or medications and increase in the number of nonspecific proliferative chronic inflammation treatment in the market, and an increase in the research and development is driving up the chronic inflammation treatment market size.
The market is experiencing a growth demand for products from North American areas as a result of the rising advancements in this field. With significant competitors like Pfizer Inc., NodThera, Abcentra, and Halia Therapeutics, Inc. actively operating in the market.
Dynamics
Growing Advancements and Clinical Trials by Key Players Drive the Growth of the Chronic Inflammation Treatment Market
Chronic inflammatory illnesses have increased in incidence and prevalence during the past few decades, particularly in Westernized nations. In order to reduce inflammation and pain, several NSAIDs are utilized; however, these anti-inflammatory drugs have a wide range of severe side effects, as opposed to plant-based natural medicines, which have anti-inflammatory medicinal properties with few to no negative side effects.
With their high drug loading capacity and potential for good target selectivity for specific cells and tissues, nanoparticles are a novel type of drug delivery system that may enhance therapeutic bioavailability and improve pharmacokinetics and pharmacodynamics (PKPD). The market is predicted to take the lead throughout the forecast period as a consequence of the aforementioned claims.
Rising Research and Development and Novel Product Launches Creates Opportunities for the Growth of the Market
As a result of years of study, a number of major manufacturers are now developing novel products and releasing them for therapeutic purposes, which is fostering the expansion of the chronic inflammation treatment market. Several treatments have been approved by the regulatory authorities for management of chronic inflammation.
For instance, on February 12, 2021, the supplemental Biologics License Application for PANZYGA - ifas 10% Liquid Preparation to treat adult patients with the uncommon neurological condition known as chronic inflammatory demyelinating polyneuropathy (CIDP), which affects the peripheral nerves, was approved by the U.S. Food and Drug Administration (FDA). In order to better serve patients' clinical needs, PANZYGA is the one and only intravenous immunoglobulin (IVIg) that has two FDA-approved maintenance dosage alternatives for CIDP.
Side Effects of Chronic Inflammation Treatment Medications will hamper the growth of the market
Several side effects are linked with the chronic inflammation treatment medications which can restrain the market's growth. The most common gastrointestinal adverse effects are abdominal pain, nausea, and diarrhea, which are experienced by 20% to 30% of patients and frequently go away on their own. Lactic acidosis is a more serious consequence that only occurs in about 1.5 per 100,000 persons each year.
Although metformin is generally thought to be rather safe, it does have one major (though uncommon) side effect known as lactic acidosis. This illness develops when the blood contains an excessive amount of lactate, a chemical produced by the muscles and red blood cells. Your lactic acid level is typically low.
For more details on this report - Request for Sample
Segment Analysis
The global chronic inflammation treatment market is segmented based type, medications, chronic inflammatory disease type, distribution channel and region.
Owing to High Demand, the Metaformin from Medication Segment Accounted for Approximately 37.1% of the Chronic Inflammation Treatment Market Share
The metaformin category from medications held the largest market share in 2022 and is expected to maintain its dominance over the forecast period due to a growth in inflammatory disorders worldwide. Throughout the world, the biguanide metformin acts as the first-line pharmaceutical treatment for type II diabetic mellitus (T2D).
Metformin is the most adaptable and therapeutically significant medication to date. The glycemic control brought on by the reduction of hepatic glucose output, the suppression of autoimmune inflammation by controlling T-cell balance, the decrease of cardiovascular mortality, the prevention of cancer, and dementia are just a few of the most significant therapeutic benefits of metformin.
Since metformin has been shown to reduce inflammation, it is a desirable medicine to test for a variety of different disorders. Additionally, leukocytes from PCOS participants with lower amounts of reactive oxygen species, TNF and IL-6 and higher levels of glutathione were found. Recent research demonstrates that metformin has an instant anti-inflammatory effect in addition to reducing Chronic Inflammation Treatment by enhancing metabolic parameters.
Geographical Penetration
North America Accounted for Approximately 42.3% of the Market Share in 2022, Owing to the Strong Presence of Major Players and Increasing Healthcare Infrastructure Investment
Due to the rising need for chronic inflammation treatment in healthcare, manufacturers in North America have chances of increasing their operations. There are many producers and suppliers in North America and owing to the quick economic growth of the region, industrial production has expanded, driving the demand for chronic inflammation treatment.
Increasing expenditure on healthcare and rising adoption among patients, advancement of technologies for medications, and increase in pharmaceutical business establishment across the region are also contributing to the growth of chronic inflammation treatment market share of this region.
It is also anticipated that the main healthcare organizations' and enterprises' collaborative research projects as well as new product development, which constantly seeks to improve available simulation training alternatives, will contribute to the expanding demand. Individuals are becoming more aware of various advanced chronic inflammatory disorders and their medications that are being utilized for treatment purposes, leading to the expansion of the market in this region. The above-mentioned factors further proves the dominance of North America on a global scale.
Competitive Landscape
The major global players in the chronic inflammation treatment market include Pfizer Inc., NodThera, Abcentra, Evommune, Inc., Sterna biologicals, Halia Therapeutics, Inc., Amgen Inc., AstraZeneca, Takeda Pharmaceutical Company Limited and Annexon, Inc. among others.
COVID-19 Impact Analysis
Russia Ukraine Conflict Analysis
Due to the low prevalence as well as absence of major market participants in this region, it is predicted that the Russia-Ukraine conflict will not have a significant effect on the worldwide chronic inflammation treatment market. The growth of the global chronic inflammation treatment market, however, is anticipated to be relatively unaffected by the import and export of raw materials over the forecast period.
By Type
- Nonspecific Proliferative
- Granulomatous Inflammation
- Foreign Body Granuloma
- Infectious Granuloma
By Medications
- Metformin
- Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
- Naproxen
- Ibuprofen
- Aspirin
By Chronic Inflammation Disease Type
- Diabetes
- Cardiovascular Diseases
- Arthritis and Joint Diseases
- Chronic Obstructive Pulmonary Disease (COPD)
- Allergies
- Others
By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
By Region
- Europe
- Germany
- U.K.
- France
- Spain
- Italy
- Rest of Europe
- South America
- Brazil
- Argentina
- Rest of South America
- Asia-Pacific
- China
- India
- Japan
- Australia
- Rest of Asia-Pacific
Key Developments
- On August 7, 2023, the enrollment of participants in the Phase I study (NCT05447546) assessing HT-6184, Halia Therapeutics' lead asset, for chronic inflammation treatment has been completed, according to the company, which is developing novel medications to treat a wide range of diseases caused by Chronic Inflammation Treatment. The NLRP3 inflammasome activity is inhibited by the first pharmacological candidate, HT-6184, which targets the protein NEK7 via an allosteric mechanism.
- On April 26,, 2023, a $50 million Series B round of financing for the clinical-stage biotechnology startup Evommune, Inc.'s research and development of novel therapies for inflammatory illnesses. Arix Bioscience, a new investor, along with EQT Life Sciences, SymBiosis, and several current investors co-led the fundraising. Several participants included Amplitude Ventures, another new investor, as well as Series A investors Andera Partners and Pivotal bioVenture Partners.
- On June 20, 2023, HYQVIA (Recombinant Human Hyaluronidase with Immune Globulin Infusion 10%) was studied as a maintenance therapy in older individuals with chronic inflammatory demyelinating polyneuropathy (CIDP), and Takeda released the entire results of the pivotal Phase 3 ADVANCE-CIDP 1 clinical trial. When HYQVIA was compared to placebo, the results revealed a clinically significant decrease in the relapse rate, and additional study revealed a prolonged time until recurrence.
Why Purchase the Report?
- To visualize the global chronic inflammation treatment market segmentation based on type, medications, chronic inflammatory disease type, distribution channel and region, as well as understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development.
- Excel data sheet with numerous data points of chronic inflammation treatment market-level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping available as excel consisting of key products of all the major players.
The global chronic inflammation treatment market report would provide approximately 69 tables, 71 figures and 195 Pages.
Target Audience 2023
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
Table of Contents
1. Methodology and Scope
- 1.1. Research Methodology
- 1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
- 3.1. Snippet by Type
- 3.2. Snippet by Medications
- 3.3. Snippet by Chronic Inflammatory Disease Type
- 3.4. Snippet by Distribution Channel
- 3.5. Snippet by Region
4. Dynamics
- 4.1. Impacting Factors
- 4.1.1. Drivers
- 4.1.1.1. Growing advancements and clinical trials by key players
- 4.1.1.2. Rising chronic inflammation diseases prevalence
- 4.1.2. Restraints
- 4.1.2.1. Side effects of chronic inflammation treatment medications
- 4.1.3. Opportunity
- 4.1.3.1. Rising research and development and novel product launches
- 4.1.4. Impact Analysis
5. Industry Analysis
- 5.1. Porter's Five Forces Analysis
- 5.2. Supply Chain Analysis
- 5.3. Pricing Analysis
- 5.4. Regulatory Analysis
- 5.5. Pipeline Anbalysis
- 5.6. Patent Analysis
- 5.7. SWOT Analysis
6. COVID-19 Analysis
- 6.1. Analysis of COVID-19
- 6.1.1. Scenario Before COVID-19
- 6.1.2. Scenario During COVID-19
- 6.1.3. Scenario Post COVID-19
- 6.2. Pricing Dynamics Amid COVID-19
- 6.3. Demand-Supply Spectrum
- 6.4. Government Initiatives Related to the Market During Pandemic
- 6.5. Manufacturers Strategic Initiatives
- 6.6. Conclusion
7. By Type
- 7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 7.1.2. Market Attractiveness Index, By Type
- 7.2. Nonspecific Proliferative *
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 7.3. Granulomatous Inflammation
- 7.3.1. Foreign Body Granuloma
- 7.3.2. Infectious Granuloma
8. By Medications
- 8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medications
- 8.1.2. Market Attractiveness Index, By Medications
- 8.2. Metformin *
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 8.3. Non-steroidal anti-inflammatory drugs (NSAIDs)
- 8.3.1. Naproxen
- 8.3.2. Ibuprofen
- 8.3.3. Aspirin
- 8.4. Statins
- 8.4.1. Simvastatin
- 8.4.2. Rosuvastatin
- 8.5. Corticosteroids
- 8.5.1. Cortisone
- 8.5.2. Prednisone
- 8.6. Herbal Supplements
9. By Chronic Inflammatory Disease Type
- 9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Chronic Inflammatory Diseases
- 9.1.2. Market Attractiveness Index, By Chronic Inflammatory Diseases
- 9.2. Diabetes *
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 9.3. Cardiovascular Diseases
- 9.4. Arthritis and Joint Diseases
- 9.5. Chronic Obstructive Pulmonary Disease (COPD)
- 9.6. Allergies
- 9.7. Others
10. By Distribution Channel
- 10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 10.1.2. Market Attractiveness Index, By Distribution Channel
- 10.2. Hospital Pharmacy *
- 10.2.1. Introduction
- 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 10.3. Retail Pharmacy
- 10.4. Online Pharmacy
11. By Region
- 11.1. Introduction
- 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 11.1.2. Market Attractiveness Index, By Region
- 11.2. North America
- 11.2.1. Introduction
- 11.2.2. Key Region-Specific Dynamics
- 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medications
- 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Chronic Inflammatory Diseases
- 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 11.2.7.1. U.S.
- 11.2.7.2. Canada
- 11.2.7.3. Mexico
- 11.3. Europe
- 11.3.1. Introduction
- 11.3.2. Key Region-Specific Dynamics
- 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medications
- 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Chronic Inflammatory Diseases
- 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 11.3.7.1. Germany
- 11.3.7.2. U.K.
- 11.3.7.3. France
- 11.3.7.4. Spain
- 11.3.7.5. Italy
- 11.3.7.6. Rest of Europe
- 11.4. South America
- 11.4.1. Introduction
- 11.4.2. Key Region-Specific Dynamics
- 12.4.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 12.4.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medications
- 12.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Chronic Inflammatory Diseases
- 12.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 12.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 12.4.5.1. Brazil
- 12.4.5.2. Argentina
- 12.4.5.3. Rest of South America
- 11.5. Asia-Pacific
- 11.5.1. Introduction
- 11.5.2. Key Region-Specific Dynamics
- 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medications
- 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Chronic Inflammatory Diseases
- 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 11.5.7.1. China
- 11.5.7.2. India
- 11.5.7.3. Japan
- 11.5.7.4. Australia
- 11.5.7.5. Rest of Asia-Pacific
- 11.6. Middle East and Africa
- 11.6.1. Introduction
- 11.6.2. Key Region-Specific Dynamics
- 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Medications
- 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Chronic Inflammatory Diseases
- 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12. Competitive Landscape
- 12.1. Competitive Scenario
- 12.2. Market Positioning/Share Analysis
- 12.3. Mergers and Acquisitions Analysis
13. Company Profiles
- 13.1. Pfizer Inc. *
- 13.1.1. Company Overview
- 13.1.2. Product Portfolio and Description
- 13.1.3. Financial Overview
- 13.1.4. Key Developments
- 13.2. NodThera
- 13.3. Abcentra
- 13.4. Evommune, Inc.
- 13.5. Sterna biologicals
- 13.6. Halia Therapeutics, Inc.
- 13.7. Amgen Inc.
- 13.8. AstraZeneca
- 13.9. Takeda Pharmaceutical Company Limited
- 13.10. Annexon, Inc.
LIST NOT EXHAUSTIVE
14. Appendix
- 14.1. About Us and Services
- 14.2. Contact Us
